Yannick L. M.
- Country
- France
- Department
- Ophthalmology
Research Overview
- Dose-ranging study of FWY003 in geographic atrophy secondary to age-related macular degeneration: randomized, double-masked, placebo-controlled trial in adults
- Evaluation of Ranibizumab Port Delivery System Refill Regimens in Neovascular Age-Related Macular Degeneration: A Phase IIIb Randomized Study
- Efficacy of Dimethyl Fumarate in Reducing Geographic Atrophy Progression in Patients with Dry Age-Related Macular Degeneration: A 12-Month Comparative Study
Data & Insights
Has run more than one trial at 66 of 109 partner sites.
Specializations
Retinal Disease Management
This investigator specializes in treating advanced forms of age-related macular degeneration (AMD), with particular focus on both wet and dry variants of the condition.
- Neovascular AMD Treatment Innovation
- Geographic Atrophy Intervention
- Long-term Disease Management
Their expertise extends to novel delivery systems and therapeutic approaches for retinal conditions.
Advanced Drug Delivery Systems
The investigator works with innovative port delivery system technologies for sustained release treatments in ophthalmology, particularly focusing on ranibizumab administration.
- Sustained Release Technologies
- Extended Treatment Intervals
- Novel Drug Administration Methods
Their work involves evaluating long-term safety and efficacy of advanced delivery mechanisms.
Therapeutic Development
The investigator studies novel therapeutic agents including danicopan and dimethyl fumarate for treating various forms of macular degeneration.
- Novel Therapeutic Compounds
- Disease Progression Management
- Visual Acuity Preservation
Their research encompasses both established and experimental treatments for retinal disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.